Top-Rated StocksTop-RatedNASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis → How Biden has already won 2024 (From Porter & Company) (Ad) Free SNDX Stock Alerts $19.27 -0.02 (-0.10%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$19.16▼$19.7950-Day Range$19.27▼$23.8052-Week Range$11.22▼$25.34Volume844,549 shsAverage Volume1.10 million shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$34.42 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Syndax Pharmaceuticals alerts: Email Address Syndax Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside78.6% Upside$34.42 Price TargetShort InterestBearish11.80% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment1.49Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.57) to ($2.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.76 out of 5 starsMedical Sector237th out of 929 stocksPharmaceutical Preparations Industry105th out of 438 stocks 3.5 Analyst's Opinion Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSyndax Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Syndax Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.80% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently decreased by 0.79%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Syndax Pharmaceuticals is -1.12. Previous Next 3.6 News and Social Media Coverage News SentimentSyndax Pharmaceuticals has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Syndax Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest6 people have searched for SNDX on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Syndax Pharmaceuticals is held by insiders.Read more about Syndax Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($3.57) to ($2.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -5.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -5.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Syndax Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Read More SNDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNDX Stock News HeadlinesMay 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Teva Pharmaceutical (TEVA), Cencora (COR)May 22, 2024 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Receives "Overweight" Rating from JPMorgan Chase & Co.May 15, 2024 | prnewswire.comSyndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of DirectorsMay 13, 2024 | markets.businessinsider.comSyndax Pharmaceuticals (SNDX) Gets a Buy from Stifel NicolausMay 12, 2024 | finance.yahoo.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | markets.businessinsider.comBuy Rating for Syndax Pharmaceuticals Amid Strong Financials and Promising Drug CandidateMay 9, 2024 | finance.yahoo.comSyndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 9, 2024 | prnewswire.comSyndax Announces Participation at the Bank of America Securities 2024 Health Care ConferenceMay 8, 2024 | msn.comSNDX Stock Earnings: Syndax Pharmaceuticals Beats EPS for Q1 2024May 8, 2024 | finanznachrichten.deSyndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateMay 8, 2024 | prnewswire.comSyndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateMay 3, 2024 | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 1, 2024 | prnewswire.comSyndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024April 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic PartnershipsApril 10, 2024 | finance.yahoo.comSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumApril 10, 2024 | prnewswire.comSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumApril 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)April 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth ProspectsApril 8, 2024 | prnewswire.comSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary SessionApril 6, 2024 | finanznachrichten.deSyndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 3, 2024 | msn.comCrinetics Pharmaceuticals gains amid pitch at Sohn charity conference (update)March 29, 2024 | msn.com20 European Cities with Highest Weed ConsumptionMarch 29, 2024 | msn.comThis longevity company is letting you check the ‘credit score’ for your health. Here are my surprising results and biological ageMarch 28, 2024 | msn.comSyndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDAMarch 28, 2024 | finance.yahoo.comSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid LeukemiaSee More Headlines Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/31/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SNDX CUSIPN/A CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees184Year FoundedN/APrice Target and Rating Average Stock Price Target$34.42 High Stock Price Target$45.00 Low Stock Price Target$23.00 Potential Upside/Downside+78.7%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.32% Return on Assets-48.46% Debt Debt-to-Equity RatioN/A Current Ratio8.93 Quick Ratio8.93 Sales & Book Value Annual Sales$139.71 million Price / Sales11.72 Cash FlowN/A Price / Cash FlowN/A Book Value$5.79 per share Price / Book3.33Miscellaneous Outstanding Shares84,990,000Free Float81,503,000Market Cap$1.64 billion OptionableOptionable Beta1.01 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael A. Metzger M.B.A. (Age 53)CEO & Director Comp: $1.1MDr. Peter Ordentlich B.Sc. (Age 55)Ph.D., Co-Founder & Chief Scientific Officer Dr. Richard A. Heyman Ph.D. (Age 67)Co-Founder Dr. Ronald M. Evans Ph.D. (Age 75)Co-Founder, Advisor and Chair of Scientific Advisory Board Dr. Michael Downes Ph.D.Co-FounderSharon KlahreVice President of Investor Relations & CommunicationsMr. Kevin McManus (Age 55)Chief People Officer Dr. Joseph Paul Eder M.D.Member of Scientific Advisory Board & Chief Medical OfficerDr. Anjali Ganguli Ph.D. (Age 47)Chief Business Officer Comp: $450.58kMr. Steven ClosterChief Commercial OfficerMore ExecutivesKey CompetitorsEvotecNASDAQ:EVOStructure TherapeuticsNASDAQ:GPCRSummit TherapeuticsNASDAQ:SMMTHarmony BiosciencesNASDAQ:HRMYNewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInsiders & InstitutionsZimmer Partners LPSold 120,100 shares on 5/17/2024Ownership: 0.182%Iron Triangle Partners LPBought 973,057 shares on 5/16/2024Ownership: 1.145%Kingdon Capital Management L.L.C.Bought 148,700 shares on 5/16/2024Ownership: 1.053%California State Teachers Retirement SystemBought 1,150 shares on 5/16/2024Ownership: 0.090%Janus Henderson Group PLCBought 22,501 shares on 5/16/2024Ownership: 0.058%View All Insider TransactionsView All Institutional Transactions SNDX Stock Analysis - Frequently Asked Questions Should I buy or sell Syndax Pharmaceuticals stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNDX shares. View SNDX analyst ratings or view top-rated stocks. What is Syndax Pharmaceuticals' stock price target for 2024? 11 brokerages have issued 12 month price objectives for Syndax Pharmaceuticals' shares. Their SNDX share price targets range from $23.00 to $45.00. On average, they anticipate the company's share price to reach $34.42 in the next twelve months. This suggests a possible upside of 78.6% from the stock's current price. View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts. How have SNDX shares performed in 2024? Syndax Pharmaceuticals' stock was trading at $21.61 at the beginning of 2024. Since then, SNDX shares have decreased by 10.8% and is now trading at $19.27. View the best growth stocks for 2024 here. When is Syndax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our SNDX earnings forecast. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.11. During the same quarter in the prior year, the business earned ($0.59) EPS. What ETFs hold Syndax Pharmaceuticals' stock? ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), ALPS Medical Breakthroughs ETF (SBIO) and Simplify Propel Opportunities ETF (SURI).Simplify Health Care ETF (PINK). What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU). When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.80%), StemPoint Capital LP (1.30%), Iron Triangle Partners LP (1.14%), Kingdon Capital Management L.L.C. (1.05%), Assenagon Asset Management S.A. (0.33%) and Zimmer Partners LP (0.18%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Peter Ordentlich, Pierre Legault and William Meury. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNDX) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks MediaElon Musk’s Final Masterpiece: “X-9840”Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.